Clinical issues in the administration of an anti-epidermal growth factor receptor monoclonal antibody, IMC-C225.
OBJECTIVE
To review the clinical safety experience of the monoclonal antibody IMC-C225, focusing on two clinically important adverse events: acne-like rash and allergic reactions. In addition, practical administration issues are discussed.


METHODS
Research articles.


CONCLUSIONS
IMC-C225 administration is well tolerated and adverse events are mild and manageable. IMC-C225 can be safely and conveniently administered once weekly in outpatient settings.


CONCLUSIONS
Because nurses will be involved with administration of IMC-C225 in the clinical setting, they must understand and be prepared to manage the acute and long-term adverse events associated with this agent.
Hollywood
Ellen
E
Department of Gastrointestinal Medical Oncology, Memorial Sloan-Kettering Hospital, 504 East 63rd St-28 N, New York, NY 10021, USA.
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000068818:Cetuximab; D002986:Clinical Trials as Topic; D003110:Colonic Neoplasms / Q000188:drug therapy; D003131:Combined Modality Therapy; D003875:Drug Eruptions / Q000209:etiology; D004342:Drug Hypersensitivity / Q000175:diagnosis / Q000209:etiology; D016903:Drug Monitoring; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D005076:Exanthema / Q000139:chemically induced; D006801:Humans; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D066246:ErbB Receptors; D000068818:Cetuximab